Sales will come, of that I have no doubt!! As to weather we will still be an independent company will, in my view, remain to be seen...The technology is state of the art and very much cutting edge.....too much for many purchasing managers budgets..... So, sales may very well be slow and with our current sales structure, it will remain so for some time. What could be a game changer is a world wide distribution deal with OCD or someone else. Even with the funding only destined to last for about a year...there could very well be some interesting news flow with in that time. I see the placing been fully subscribed for. Regarding the open offer, I would say that there are probably many who like me bought in @ 40p and said, never again and are still holding. Remember, there has been very little volume with that fall from the last offer.......I have over subscriber yet again...possible more fool me, or great investment move... But definitely....never again....LOL...
Faster, cheaper, more beneficial and efficient, solves patient miss identification and sample contamination, resolves problems of storage and transport, multi testing at patients bedside........etc. Hell no Hospital is going to buy a product that delivers such benefits so expediently! WB999 I jest of course but if I with zero medical knowledge can see the necessity for Proxima I'm sure the professionals can. Production and quality contro are Sphere's next challenge, delivery will be a by product of the former with routes to market the least of the companies problem. We all have our doubts but as you rightly say massively derisked from 40 to 16 when logic tells you it should have been 40 to 60/80. I am much more hopeful than I was this time last year!
It is a very different company, it now has a product, a massive difference. Question now is do people want to buy it and can the co deliver? Early signs are that the original product concept is still valid, I don't see any changes in terms of the product or strategy, which is good. One would imagine if the product is as good as it seems the uptake will come albeit slowly in the medical field. We now have a star fund manager backing the co as well. I have to imagine that acquirers wil be starting to take notice. So 16p versus 40p with so much of the risk reduced seems a good deal. Still many of us in for a while are still hurting and it will be a while before I congratulate the BoD taking the price from 40p to 16p. This is a truly monumental dilution and a result of the constant drift down due to poor investor communication in my view. Hopefully, we have now turned a corner and the only way is up from here.
The last 40p raise was snubbed by shareholders only 15% (1.6m shares) taken up, this of course well before CE Mark days though the agreement with OCD had just been signed. So in terms of progress we are a completely different company today and bear no comparison to one just finalising the development of P3 and talking about the operational capabilities re volumes & production. The progress since then has been staggering...... even if behind schedule. I'm sure holders have factored all this in before applying for open offer shares. How many of those in at the 40p raise are still on the books? I suppose natural wastage would have seen many either drop out or blank the offer but counterbalanced by new investors since. We now have the Woodford involvement announced 13 April so none of the subsequent buyers will be able to apply for the open offer which went xr 13/14 April? That will limit the take up! Fairly sure we will all get what we applied for, they need the money.Lastly since 13/4 a total nos of c 2.4m shares traded with c 160 bargains recorded.
Right! i think it's 1 May they get credited to your account.
RE: Good result!
John...If you look at page 54 of the offer document, it says that the result of the open offer is expected to be announced n the 29 April 2015.... So we should know on Wednesday......
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.